MBOT
Microbot Medical Inc.Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-04-01 | Stockburger Aileen Ptucha |
Director |
Award↑
|
Stock Option (Right to Buy)
|
10,000 |
| 2026-04-01 | Madden Martin J. |
Director |
Award↑
|
Stock Option (Right to Buy)
|
10,000 |
| 2026-04-01 | Laxminarain Prattipati |
Director |
Award↑
|
Stock Option (Right to Buy)
|
10,000 |
| 2026-04-01 | Burell Scott R |
Director |
Award↑
|
Stock Option (Right to Buy)
|
10,000 |
| 2026-04-01 | Wenderow Tal Baruch |
Director |
Award↑
|
Stock Option (Right to Buy)
|
10,000 |
| 2026-04-01 | Wilson David James |
Director |
Award↑
|
Stock Option (Right to Buy)
|
10,000 |
| 2026-02-18 | Vaknin Rachel |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
105,000 |
| 2026-02-18 | Diaz-Cartelle Juan |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
105,000 |
| 2026-02-18 | Gadot Harel |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
480,000 |
| 2026-02-18 | Sharon Simon |
General Manager, CTO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended (the "Plan"): (a) on August 18, 2026, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration or forfeiture pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
105,000 |
| 2025-02-05 | Diaz-Cartelle Juan |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 5, 2025, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
42,000 |
| 2025-02-05 | Sharon Simon |
General Manager, CTO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 5, 2025, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
43,750 |
| 2025-02-05 | Vaknin Rachel |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 5, 2025, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
48,125 |
| 2025-02-05 | Gadot Harel |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 5, 2025, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
228,000 |
| 2025-01-28 | Burell Scott R |
Director |
Award↑
|
Stock Option (Right to Buy)
|
10,000 |
| 2025-01-28 | Wilson David James |
Director |
Award↑
|
Stock Option (Right to Buy)
|
20,000 |
| 2025-01-28 | Madden Martin J. |
Director |
Award↑
|
Stock Option (Right to Buy)
|
10,000 |
| 2025-01-28 | Stockburger Aileen Ptucha |
Director |
Award↑
|
Stock Option (Right to Buy)
|
10,000 |
| 2025-01-28 | Laxminarain Prattipati |
Director |
Award↑
|
Stock Option (Right to Buy)
|
10,000 |
| 2025-01-28 | Wenderow Tal Baruch |
Director |
Award↑
|
Stock Option (Right to Buy)
|
10,000 |
| 2024-12-17 | Wilson David James |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2024-02-26 | Vaknin Rachel |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Such options, granted on February 26, 2024, were performance-based options the vesting of which was subject to the satisfaction of milestones. On February 5, 2025, the Compensation Committee of the Board of Directors of the Issuer confirmed and determined that the milestones with respect to 4,375 options have been met and, accordingly, vested. |
Stock Option (Right to Buy)
|
4,375 |
| 2024-02-26 | Diaz-Cartelle Juan |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Such options, granted on February 26, 2024, were performance-based options the vesting of which was subject to the satisfaction of milestones. On February 5, 2025, the Compensation Committee of the Board of Directors of the Issuer confirmed and determined that the milestones with respect to 10,500 options have been met and, accordingly, vested. |
Stock Option (Right to Buy)
|
10,500 |
| 2024-02-26 | Sharon Simon |
General Manager, CTO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Such options, granted on February 26, 2024, were performance-based options the vesting of which was subject to the satisfaction of milestones. On February 5, 2025, the Compensation Committee of the Board of Directors of the Issuer confirmed and determined that the milestones with respect to 8,750 options have been met and, accordingly, vested. |
Stock Option (Right to Buy)
|
8,750 |
| 2024-02-26 | Gadot Harel |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Such options, granted on February 26, 2024, were performance-based options the vesting of which was subject to the satisfaction of milestones. On February 5, 2025, the Compensation Committee of the Board of Directors of the Issuer confirmed and determined that the milestones with respect to 12,000 options have been met and, accordingly, vested. |
Stock Option (Right to Buy)
|
12,000 |
| 2024-02-26 | Gadot Harel |
Director |
Award↑
|
Stock Option (Right to Buy)
|
79,567 |
| 2024-02-22 | Gadot Harel |
Director |
Award↑
|
Stock Option (Right to Buy)
|
80,000 |
| 2024-02-22 | Gadot Harel |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 22, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
80,000 |
| 2024-02-22 | Diaz-Cartelle Juan |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 22, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
17,500 |
| 2024-02-22 | Vaknin Rachel |
Chief Financial Officer |
Award↑
|
Stock Option (Right to Buy)
|
17,500 |
| 2024-02-22 | Sharon Simon |
General Manager, CTO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 22, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
17,500 |
| 2024-02-22 | Sharon Simon |
General Manager, CTO |
Award↑
|
Stock Option (Right to Buy)
|
17,500 |
| 2024-02-22 | Vaknin Rachel |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on August 22, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
17,500 |
| 2023-11-02 | Laxminarain Prattipati |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Stock Option (Right to Buy)
|
74,218 |
| 2023-11-02 | Burell Scott R |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Stock Option (Right to Buy)
|
74,218 |
| 2023-11-02 | Madden Martin J. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Stock Option (Right to Buy)
|
74,218 |
| 2023-11-02 | Wenderow Tal Baruch |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Stock Option (Right to Buy)
|
74,218 |
| 2023-11-02 | Stockburger Aileen Ptucha |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Stock Option (Right to Buy)
|
74,218 |
| 2023-11-02 | Bornstein Yoseph |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Stock Option (Right to Buy)
|
74,218 |
| 2023-08-01 | Gadot Harel |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on February 1, 2024, the options shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
80,000 |
| 2023-08-01 | Morag Eyal |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on February 1, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
17,500 |
| 2023-08-01 | Sharon Simon |
General Manager, CTO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on February 1, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
17,500 |
| 2023-08-01 | Vaknin Rachel |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on February 1, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
17,500 |
| 2023-01-17 | Sharon Simon |
General Manager, CTO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on July 17, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
35,000 |
| 2023-01-17 | Morag Eyal |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on July 17, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan. |
Stock Option (Right to Buy)
|
35,000 |
| 2022-12-21 | Vaknin Rachel |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on June 21, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Stock Option (Right to Buy)
|
13,000 |
| 2022-12-21 | Gadot Harel |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on June 21, 2023, the options shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Stock Option (Right to Buy)
|
160,000 |
| 2022-09-21 | Madden Martin J. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 21, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Stock Option (Right to Buy)
|
16,637 |
| 2022-09-21 | Bornstein Yoseph |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 21, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Stock Option (Right to Buy)
|
16,637 |
| 2022-09-21 | Wenderow Tal Baruch |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan: (a) on March 21, 2023, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock. |
Stock Option (Right to Buy)
|
16,637 |